WT1 and acute myeloid leukemia: One of the promising vaccine candidates, galinpepimut-S, has shown the ability to induce WT1-specific T-cell responses and was well tolerated in a Phase II clinical trial (NCT02648490) involving AML patients in remission, indicating its potential in preventing disease relapse [60].